Skip to main content
. 2017 Jun 6;2017(6):CD012143. doi: 10.1002/14651858.CD012143.pub2
Methods For characteristics see Anderson 2014a1
Participants
Interventions
Outcomes
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel (performance bias) All outcomes Unclear risk Investigators and participants were blinded to the study drug treatment regimen, but it was not stated how the blinding was maintained.
Blinding of outcome assessment (detection bias) All outcomes Unclear risk Not described
Incomplete outcome data (attrition bias) All outcomes Unclear risk More than 5% of participants did not complete the study (19%), according to study protocol
Selective reporting (reporting bias) Low risk A protocol was found (NCT01074008)
Vested‐interest bias High risk This study was funded by AbbVie
Other bias Low risk The trial appeared to be free of other components that could put it at risk of bias